Can your Child's DNA predict the best ADHD drug?

NCT ID NCT06221358

Recruiting now Knowledge-focused Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether a child's genetic makeup influences how well they respond to the ADHD medication methylphenidate. Researchers will track symptom changes and side effects in 400 participants aged 6-24 across Western Canada. The goal is to find genetic markers that could one day help personalize ADHD treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: methylphenidate
What this could lead to: If successful, this could help doctors choose the right ADHD medication based on a child's genes, reducing trial-and-error.
What could go wrong: This is an observational study, not a treatment trial. It may not find clear genetic links, and results may not change practice for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Contacts and locations

Locations

University of Calgary
RECRUITING

Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.